Dr. Andrej Spec, MD
Infectious Disease (Infectious Disease Physician)
620 S Taylor Ave, Div Im Infectious Disease, Ste 100
Saint Louis, MO 63110
- Medicare participating
At a glance
- Medical school
- Chicago College of Medicine and Surgery (2010)
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 81
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Medical school: Chicago College of Medicine and Surgery
- 2010Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Infectious Disease Physician primary
MO license 2016000564
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Barnes Jewish Hospital Saint Louis, MO
- Missouri Baptist Medical Center Saint Louis, MO
- Alton Memorial Hospital Alton, IL
Medical groups
- Washington University (3,029 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 81
- Services billed
- 141
- Patients’ average age
- 67
| Service | Times | Patients |
|---|---|---|
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 36 | 35 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 35 | 22 |
| Established patient office or other outpatient visit, 30-39 minutes | 31 | 26 |
| Established patient office or other outpatient visit, 40-54 minutes | 17 | 15 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 17 | 17 |
| Established patient office or other outpatient visit, 20-29 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ertapenem (ertapenem sodium) | 24 |
| Cresemba (isavuconazonium sulfate) | 22 |
| Itraconazole | 13 |
| Methenamine Hippurate Other prescribers in Saint Louis, MO | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 3 payments worth $8,532 in total to this clinician.
| Gilead Sciences, Inc. | $6,660 |
|---|---|
| Astellas Pharma US Inc | $1,872 |
| Consulting Fee | $8,532 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Gilead Sciences, Inc. Apr 9, 2025 | Consulting Fee AmBisome · OTHER Company’s description;3962804;GTF;11099456 | $3,330 |
| Gilead Sciences, Inc. Apr 9, 2025 | Consulting Fee AmBisome · OTHER Company’s description;3982146;GTF;11099456 | $3,330 |
| Astellas Pharma US Inc Dec 17, 2025 | Consulting Fee Cresemba · Infectious Diseases | $1,872 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $167,909 in research payments for these studies, mostly to the institutions running them.
- Comparison of Isavuconazole vs. Standard of Care in the Treatment of Endemic Mycoses using a Large Medicare Database, 2007-2018
Astellas Pharma Global Development - Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex
Insmed, Inc. · Completed · NCT04677569 - Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)
Paratek Pharmaceuticals, Inc. · Completed · NCT04922554
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.